Addendum

Concizumab (haemophilia B) – Addendum to Project A25-56

Status
Status: Commission completed
Project no.
A25-115
Last updated

Report documents

  1. Addendum

    Concizumab (haemophilia B) Addendum to Project A25-56

    published on
    Document type
    PDF document, 366 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-115_en

Dossier assessment

Indication:

Routine prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency) and factor IX inhibitors and of 12 years of age or more

Result of dossier assessment:

Unchanged after addendum: Added benefit not proven

Additional information

Federal Joint Committee (G-BA)

16-10-2025 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A25-115
Commission
Commission awarded on 09.09.2025 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Haematology
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://doi.org/10.60584/A25-115_en

Connected Projects

  1. Dossier assessment

    Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-56
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form